Phase 2 N=13 Tenecteplase in Patients With COVID-19
COVID-19 · Respiratory Failure · ARDS
Primary: Number of Participants Free of Respiratory Failure — 5; 2 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=108 Topical NVN1000 for the Treatment of External Genital and Perianal Warts
Genital Warts · Perianal Warts
Primary: Efficacy: Complete Clearance of Baseline External Genital and Perianal Warts at or Before Week 12 — 2; 5; 2; 10 Participants
Phase 2 N=14 Non-intrusive Detection of Temporary Neurologic Impairment By Opioids
Healthy
Primary: Oculo-Cognitive Addition Test (OCAT) Completion Time — 57.22; 57.22; 59.56; 58.18 seconds
Phase 2 N=66 Efficacy and Tolerability Study of Two Dosing Regimens of CTP-543 in Adults With Alopecia Areata
Alopecia Areata
Primary: Relative Change From Baseline in Severity of Alopecia Tool (SALT) Score at Week 24 — 58.44; 51.96 percent change
Phase 2 N=24 A Trial of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers
Advanced Gynecological Cancers · Ovarian Cancer · Cervical Cancer
Primary: Number of Treatment-emergent AEs of Vigil + Atezolizumab — 0; 0; 0; 0 adverse events
Phase 2 N=73 Cabergoline for Lactation Inhibition After Second-Trimester Abortion or Loss
Lactation Suppressed
Primary: Number of Participants Reporting Breast Pain — 10; 32 Participants
Phase 2 N=235 An Investigational Immuno-therapy Study of Experimental Medication BMS-986179 Given Alone and in Combination With Nivolumab
Malignant Solid Tumor
Primary: Number of Participants With Drug Related AEs, SAEs, AEs Leading to Discontinuation and Deaths. — 7; 4; 3; 4 Participants
Phase 2 N=1,601 Study to Gather Information About the Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following an Acute Heart Attack
Acute Myocardial Infarction
Primary: Efficacy - Number of Participants With Composite of CV Death, MI, Stroke and Stent Thrombosis (ST) — 27; 24; 22; 22 Participants — p== 0.8439
Phase 2 N=143 Evaluation of ETC-1002 in Participants With Hypercholesterolemia and Hypertension
Hypercholesterolemia · Hypertension
Primary: Percent Change From Baseline in Calculated Low-density Lipoprotein Cholesterol (LDL-C) to Week 6 — 3.16; -21.08 Percent Change — p=<0.0001
Phase 2 N=180 The Randomized OPTIMAL-ACT Trial
Coronary Artery Disease · Ischemic Heart Disease · Anticoagulant-induced Bleeding
Primary: Bleeding — 14; 15; 15 Participants
Phase 2 N=23 Adjunctive Ganaxolone Treatment (Part A) in TSC Followed by Long-term Treatment (Part B)
Tuberous Sclerosis
Primary: Percent Change From Baseline in 28-day Seizure Frequency Through the End of 12-Week Treatment Period — -16.61 Percent change
Phase 2 N=14 Pentoxifylline, Atorvastatin, and Vitamin E in Treating Patients With Erectile Dysfunction After Radiation Therapy for Prostate Cancer
Male Erectile Disorder · Prostate Adenocarcinoma · Erectile Dysfunction, CTCAE
Primary: Change in International Index of Erectile Function (IIEF) Scores — 0; 0; 0 Participants
Phase 2 N=23 A Trial of Poly-ICLC in the Management of Recurrent Pediatric Low Grade Gliomas
Brain Tumors
Primary: Progression Free Survival — 70 percentage of no progression
Phase 2 N=951 An add-on Study to the FIGARO-DKD Study Called FIGARO-BM to Learn About the Link Between Biomarkers (Substances in the Blood Used as Indicators of Biological Processes, Disease Processes or Responses to Medication) and Finerenone in FIGARO-DKD Participants
Chronic Kidney Disease · Type 2 Diabetes Mellitus
Primary: Mean Change in Plasma Biomarker Levels After 36 Months of Treatment Versus 4 Months of Treatment in a Set of 27 Pre-defined Biomarkers — 1.014; 1.062; 0.979; 1.131 Ratio…
Phase 2 N=36 A Safety, Pharmacokinetics, and Pharmacodynamics Study of ABX464 in HIV-1 Seronegative and Seropositive Adults
HIV Infections · Health Volunteers
Primary: Area Under the Curve (AUC) of ABX464 in Sera — 306.0; 63.7; 63.7; 119.8 ng*h/mL